ArticleJB & JS open access
Dual Antibiotic Prophylaxis with Addition of Doxycycline Does Not Lower Periprosthetic Infection Rate in Primary Directed Anterior Total Hip Replacement: A Cohort Study on 7,917 Patients.
Article in JB & JS open access. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Periprosthetic joint infections (PJI) caused by Methods: A total of 4,430 primary THAs receiving CEF prophylaxis were compared with 3,487 THAs receiving CEF+DOX prophylaxis. The institutional AB-prophylaxis was changed from cefuroxime 1.5-3 g (CEF group) alone to cefuroxime 1.5-3 doxycycline 300 mg (CEF+DOX group). A multivariable binary logistic regression analysis to evaluate the association between CEF vs. CEF+DOX and the occurrence of PJI (according to the International Consensus Meeting 2018) was performed with dropping 3 months before and after the change (covariates: American Society of Anesthesiologists, Charlson Comorbidity -Index, age, body mass index [BMI], smoking status, and diabetes mellitus [DM]). The primary outcome was the incidence of PJI following THA after a minimum follow-up of 1 year, with an accompanying analysis of the microbiological spectrum. Results: In total, 7,917 (age: 65.8 (65.5; 66.0) years; female: 61.2%; male: 38.8%) THA were analyzed for this study. After a median follow-up of 4.3 years (interquartile-range: 2.0-6.2), no significant difference in the incidence of septic revision was observed between the CEF and CEF+DOX therapy with an infection rate of 1.3% and 1.0%, respectively (p = 0.172). The septic-free revision rate at 1 year was 99.0% in the CEF group and 99.1% in the CEF+DOX group (p = 0.541). Due to the longer follow-up, the CEF group experienced more THA with aseptic loosening compared to the CEF+DOX group. The type of AB prophylaxis was not associated with a clinically relevant higher risk of PJI (odds ratio [OR] = 1.03; 95% CI: 0.99-1.07; p = 0.052). Only BMI demonstrated a significant association with PJI (OR = 1.12; 95% CI: 1.09-1.16; p < 0.001). In the CEF+DOX group, Conclusion: This study showed no superiority in the rate of PJI between CEF+DOX and CEF alone in DAA THA. DOX does not prevent Level of Evidence: Diagnostic Level III. See Instructions for Authors for a complete description of levels of evidence.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.